title: CI-980 in advanced melanoma and hormone refractory prostate cancer.
abstract: BACKGROUND
  CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines.
  
  
  METHODS
  13 malignant melanoma patients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory prostate cancer patients, including 4 who had received prior chemotherapy, were treated in 2 separate NCI-supported clinical trials. Subjects received a recommended phase II dose of CI-980 of 4.5 mg/m2/day by continuous infusion for 72 hours every 3 weeks.
  
  
  RESULTS
  No activity was seen in either study. Toxicity was tolerable with neutropenia being the most common, significant toxicity. Among the melanoma patients, 15% and 31% developed grade 3 and grade 4 neutropenia, while 7% and 38% of the prostate patients developed grade 3 and grade 4 neutropenia, respectively.
  
  
  CONCLUSIONS
  CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer.
authors.affiliation: Department of Medicine, Cancer Research Center, University of Chicago, Illinois, USA.
authors.forename: C W
authors.initials: CW
authors.lastname: Ryan
authors.forename: K L
authors.initials: KL
authors.lastname: Shulman
authors.forename: J M
authors.initials: JM
authors.lastname: Richards
authors.forename: J W
authors.initials: JW
authors.lastname: Kugler
authors.forename: J A
authors.initials: JA
authors.lastname: Sosman
authors.forename: R H
authors.initials: RH
authors.lastname: Ansari
authors.forename: E E
authors.initials: EE
authors.lastname: Vokes
authors.forename: N J
authors.initials: NJ
authors.lastname: Vogelzang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002219:Carbamates / Q000009:adverse effects / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D002219:Carbamates; D011719:Pyrazines; D011725:Pyridines; C072383:canertinib dihydrochloride